Burning questions stay on Trump drug value govt order
WASHINGTON — President Trump’s govt order to decrease drug costs via sweeping, cross-agency motion left leaders within the pharmaceutical trade scrambling Monday to make sense of what could also be forward — and learn how to reply.
The announcement was lengthy on messaging, however quick on particulars. That will clarify why share costs for a lot of pharmaceutical and biotech firms dropped within the hours earlier than the announcement, however gained floor after buyers took inventory of Trump’s strikes.
“This has the texture of a Reality Social put up within the type of an govt order,” mentioned Brian Reid of Reid Strategic, a guide who works with drug firms on pricing and entry points. “It’s a bully pulpit transfer. There’s no precise directions on learn how to use the regulation to effectuate this. It’s merely an announcement that he needs costs to be decrease.”
This text is unique to STAT+ subscribers
Unlock this text — plus each day intelligence on Capitol Hill and the life sciences trade — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
